Yoshino, Takayuki http://orcid.org/0000-0002-0489-4756
Di Bartolomeo, Maria
Raghav, Kanwal http://orcid.org/0000-0003-1311-4173
Masuishi, Toshiki
Loupakis, Fotios
Kawakami, Hisato http://orcid.org/0000-0002-3280-4850
Yamaguchi, Kensei
Nishina, Tomohiro
Wainberg, Zev
Elez, Elena http://orcid.org/0000-0002-4653-6324
Rodriguez, Javier
Fakih, Marwan
Ciardiello, Fortunato http://orcid.org/0000-0002-4661-5540
Saxena, Kapil
Kobayashi, Kojiro
Bako, Emarjola
Okuda, Yasuyuki
Meinhardt, Gerold
Grothey, Axel
Siena, Salvatore http://orcid.org/0000-0002-2681-2846
Di Bartolomeo, Maria
,
Funding for this research was provided by:
Daiichi Sankyo and AstraZeneca
Article History
Received: 23 August 2022
Accepted: 12 April 2023
First Online: 7 June 2023
Competing interests
: The authors declare the following competing interests: T.Y. has received support for the present manuscript from Daiichi Sankyo and has received institutional grants or contracts from Taiho Pharmaceutical, Sumitomo Dainippon, Ono Pharmaceutical, Chugai Pharmaceutical, Amgen, Parexel International MSD, and Sanofi KK. M.D.B. has received research funding, provision of study materials, medical writing, and article processing charges from Daiichi Sankyo. K.R. has received institutional research funding from Daiichi Sankyo; has received grants or contracts from Roche/Genentech; and has received honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from Daiichi Sankyo. T.M. has received institutional grants or contracts from MSD, Daiichi Sankyo, Ono Pharmaceuticals, and Novartis, and has received honoraria from Takeda, Chugai Pharmaceuticals, Merck Bio Pharma, Taiho, Bayer, Eli Lilly Japan KK, Yakult Honsha, Sanofi, Daiichi Sankyo, Ono Pharmaceuticals, and BMS. H.K. has received grants or contracts from Chugai Pharmaceuticals, Taiho Pharmaceuticals, and Eisai Co. Ltd; has received consulting fees from BMS, Eli Lilly Japan KK, Ono Pharmaceuticals, Daiichi Sankyo, and Taiho Pharmaceuticals; and has received honoraria from BMS, Bayer Yakuhin Ltd, Eli Lilly Japan KK, MSD KK, Ono Pharmaceuticals, Chugai Pharmaceuticals, Daiichi Sankyo, Takeda Pharmaceuticals, and Taiho Pharmaceuticals. K.Y. has received institutional support for the present manuscript from Daiichi Sankyo and has received honoraria for lectures from Daiichi Sankyo. T.N. has received institutional support for the present manuscript from Daiichi Sankyo and has received honoraria from Ono Pharmaceuticals, Taiho Pharmaceuticals, Takeda Pharmaceuticals, Chugai Pharmaceuticals, and Daiichi Sankyo. Z.W. has received consulting fees from Merck, Ibsen, Eli Lilly, Five Prime, QED, Molecular Templates, Daiichi Sankyo, AstraZeneca, Bayer, Novartis; has received support for attending meetings and/or travel from Lilly, Merck, Novartis, and Daiichi Sankyo; and has participated on a data safety monitory board or advisory board for Array. E.E. has received grants or contracts from F. Hoffman La-Roche, BMS, Servier, Amgen, Merck Serono, Array Biopharma, Sanofi, and Bayer; institutional funds for grants from Array Biopharma, MSD, AbbVie, Amgen, GlaxoSmithKline, AstraZeneca, Merck Sharpe and Dohme Corp, BMS, Novartis, Boehringer Ingelheim, Hoffman La-Roche, MedImmune, Pierre-Fabre, and Sanofi Aventis; has received consulting fees from Hoffman La-Roche, BMS, Servier, Amgen, Merck Serono, Array Biopharma, Sanofi, Bayer; has received honoraria from F. Hoffman La-Roche, BMS, Servier, Amgen, Merck Serono, Array Biopharma, Sanofi, Bayer; has received payment for expert testimony from F. Hoffman La-Roche, BMS, Servier, Amgen, Merck Serono, Array Biopharma, Sanofi, Bayer; and has received support for attending meetings and/or travel from F. Hoffman La-Roche, BMS, Amgen, Merck Serono, Array Biopharma, Sanofi, Bayer. M.F. has received institutional grants or contracts from AstraZeneca, Novartis, and Amgen; has received consulting fees from HalioDx, Incyte Corporation, Mirati, Pfizer, Taiho, and Zhuhai Yufan Biotech; has received honoraria from Amgen and Guardant360; and has participated on a data safety monitoring board or advisory board for Amgen, Seattle Genetics, GlaxoSmithKline, Array Biopharma, Mirati, and Bayer. F.C. has served as an advisor and speaker for Roche, Amgen, Merck Serono, Pfizer, Sanofi, Bayer, Servier, Bristol Myers Squibb, Celgene, and Eli Lilly; and received institutional research grants from Bayer, Roche, Merck Serono, Amgen, AstraZeneca, and Takeda. A.G. has received institutional medical writing support from Daiichi Sankyo; has received consulting fees from Daiichi Sankyo, Bayer, Merck/MSD, Genentech/Roche, Natera, and BMS; has received honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from Bayer, Genentech/Roche, and Merck/MSD; and has participated on a data safety monitoring board or advisory board for Regeneron. K.S., K.K., E.B., Y.O., and G.M. are full-time employees of Daiichi Sankyo. F.L., J.R., and S.S. have nothing to declare.